SK Bioscience announced on the 28th, citing IMS data, a global market research institute, that its self-developed shingles vaccine Sky Zoster achieved the top share in sales in the domestic market last year.

According to SK Bioscience, Sky Zoster's domestic market share last year reached 54% based on sales volume. Quarterly by quarter, 51% in the first quarter, 52% in the second quarter, 56% in the third quarter, and 57% in the fourth quarter. It is explained that it broke the record for the largest market share every quarter.

Sky Zoster is the world's second and Korea's first shingles vaccine developed by SK Bioscience based on its own technology. SK Bioscience explained that Sky Zoster